Febuxostat, a potent non-purine selective Xanthine Oxidase( XO) inhibitor, inhibits both oxidized and reduced types of XO unlike allopurinol. As a result of its selectivity and structural differences, febuxostat tends to cause fewer adverse events when compared with allopurinol
With advantage of a fixed daily dose 120mg
No dose adjustment is necessary in patients with mild or moderate renal impairment
No hypersensitivity profile unlike allopurinol
Reduces higher rates of treatment-related complications and costs